PlainPatent
USPTO 2015–2025 USPTO PatentsView US Corporation

Vertex Pharmaceuticals Incorporated

USPTO PatentsView assignee record - 334 granted patents across 24 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Explore the portfolio See the ranking
334
Total patents granted
24
CPC technology areas
23.5
Avg claims per patent
-2%
5-year filing velocity

The verdict

Vertex holds 334 US patents across 24 technology areas, rank #1,267 of 50,000 tracked assignees.

#1,267
of 50,000 US assignees by volume
Top 5%
by Innovation Score (57.9/100)
23.5
avg claims per patent
-2%
filing velocity, last 5 yrs

Portfolio overview

Vertex Pharmaceuticals Incorporated has been granted 334 US utility patents between 2015 and 2025, placing Vertex Pharmaceuticals Incorporated at rank #1,267 across all assignees tracked by PlainPatent. This portfolio spans 24 distinct Cooperative Patent Classification (CPC) subclasses, averaging 23.5 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Vertex Pharmaceuticals Incorporated is one of the more focused assignees in the PatentsView dataset. By volume, Vertex sits between Cummins Emission Solutions Inc. (335 patents, rank #1,263) and Cartier International Ag (332 patents, rank #1,271) - the closest US assignees by grant volume. The composite Innovation Score of 57.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 165 grants, compared with 169 in the 2015–2019 window, a -2% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Vertex Pharmaceuticals Incorporated's 23.5 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while a multi-domain presence across 24 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Vertex Pharmaceuticals Incorporated against peers pursuing similar technology classes.

Who files at Vertex's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Vertex holds 334 patents at rank #1,267, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Vertex

By rank, the assignees closest to #1,267 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Vertex's primary technology class.

Vertex's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

58 Top 5% higher than 95% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). Below this entry. 50–60: 5,058 US assignees (10%). This entry sits in this band. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

2030405060 20152016201720182019202020212022202320242025 31
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Vertex Pharmaceuticals Incorporated patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 57 17.1%
2016 34 10.2%
2017 28 8.4%
2018 26 7.8%
2019 24 7.2%
2020 33 9.9%
2021 24 7.2%
2022 23 6.9%
2023 23 6.9%
2024 31 9.3%
2025 31 9.3%

Which technologies does Vertex Pharmaceuticals Incorporated patent most?

Top 15 of 24 technology areas

Patent Moat Analysis

Portfolio Volume Moderate
Tech Breadth Multi-domain
Claim Depth Complex
Velocity Declining

Where it ranks

Overall rank by patents

#1,267

Across all tracked assignees

Innovation Score

57.9 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Vertex Pharmaceuticals Incorporated hold?
Vertex Pharmaceuticals Incorporated holds 334 US granted patents filed between 2015 and 2025, spanning 24 technology areas.
What is Vertex Pharmaceuticals Incorporated's Innovation Score?
Vertex Pharmaceuticals Incorporated has an Innovation Score of 57.9 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Vertex Pharmaceuticals Incorporated focus on?
Vertex Pharmaceuticals Incorporated's top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 270 patents. The company has filed patents in 24 CPC subclasses total.
Is Vertex Pharmaceuticals Incorporated's patent filing rate increasing or decreasing?
Vertex Pharmaceuticals Incorporated's recent filing velocity is -2% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Vertex Pharmaceuticals Incorporated's patents?
Vertex Pharmaceuticals Incorporated's patents average 23.5 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Vertex Pharmaceuticals Incorporated patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Vertex's 334 grants land it in the top 5% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Vertex ranks #1,267 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.